At Apellis, we combine courageous science and compassion to develop life-changing medicines for some of the most challenging diseases patients face.
Our goal is to transform treatment for a broad range of debilitating diseases by controlling a part of the immune system known as the complement cascade.
We ushered in the first new class of complement medicine in 15 years, and now have two approved medicines targeting C3, the central protein in the cascade. These include the first-ever FDA approved therapy for geographic atrophy, a leading cause of blindness around the world.
With nearly a dozen clinical and pre-clinical programs underway, we believe we have only begun to unlock the potential of targeting C3 across rare, retinal, and neurological diseases and are further exploring what is possible by targeting C3.
